Virobay
2006 – Founded as a protease inhibitor drug discovery and development company
2007 – Filed IND and initiated Phase I trial with lead protease inhibitor as an oral treatment for Hepatitis C
2007 – In-licensed cathepsin protease inhibitor assets; including VBY-129, a selective cathepsin S inhibitor which completed phase 1 clinical development
2008 – Virobay assets solve the chemical challenge of cathepsin inhibitor design; multiple orally bioavailable development candidates are poised for Phase I
2010 – Virobay closes Series B financing
Welcome to Virobay, leaders in protease inhibitor design.
At Virobay we are developing protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer.
Our virtual model of drug discovery and development combines extensive in-house expertise with the resources of contract research and manufacturing facilities worldwide for cost effective and efficient development.
Our Pipeline
(Clinical Candidate) |
||||
|---|---|---|---|---|
| Autoimmune Diseases | ||||
| VBY-129 | X | |||
| VBY-891 | X | |||
| VBY-036 | X | |||
| Neuropathic Pain | ||||
| VBY-891 | X | |||
| VBY-036 | X | |||
| VBY-285 | X | |||
| Liver Fibrosis | ||||
| VBY-376 | X | |||
| Oncology | ||||
| VBY-825 | X | |||
